Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc. (USA) holds 0 active US FDA Type II Drug Master Files and 9 inactive and has DMF or CEP filings on record for 8 active ingredients. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Teva Pharmaceuticals USA, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/teva-pharmaceuticals-usa-inc
Overview
Teva Pharmaceuticals USA, Inc. is a subsidiary of Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. The company specializes in the development, production, and marketing of generic and specialty medicines.
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Teva Pharmaceuticals USA, Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Teva Pharmaceuticals USA, Inc. holds 0 active (9 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- AMOXICILLIN SODIUMInactive2005-04-08
- CEFACLOR USPInactive1999-11-19
- OXACILLIN SODIUMInactive1998-09-01
- CEFAZOLIN SODIUMInactive1998-09-01
- CEPHRADINEInactive1998-09-01
- CYCLACILLINInactive1998-09-01
- CLOXACILLIN SODIUMInactive1998-09-01
- PENICILLIN V POTASSIUMInactive1998-04-30
- CEPHALOSPORIN GInactive1990-07-11
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class II2026-10-21
Presence of Foreign Tablets/Capsules
- recall — Class II2026-09-09
Presence of Foreign Tablets/Capsules
- 4832026-07-20
In-process materials characteristics testing
- recall — Class II2026-05-13
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- recall — Class II2026-04-29
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
- recall — Class II2026-04-15
CGMP Deviations: use of an unapproved raw material
- recall — Class II2026-04-15
Superpotent and Subpotent
- recall — Class II2026-04-15
Superpotent and Subpotent
- recall — Class II2026-04-15
CGMP Deviations: use of an unapproved raw material
- recall — Class II2026-04-15
CGMP Deviations: use of an unapproved raw material
- recall — Class II2026-04-01
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- recall — Class II2026-04-01
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- recall — Class II2026-04-01
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- recall — Class II2026-03-11
Failed Dissolution Specifications
- recall — Class II2026-03-11
Failed Dissolution Specifications
- recall — Class II2026-03-11
Failed Dissolution Specifications
- recall — Class II2026-03-11
Failed Dissolution Specifications
- recall — Class III2025-12-10
Defective Container - A defect in the side-seal which allows leakage of product.
- recall — Class II2025-11-12
Subpotent drug; Clavulanate Potassium component
- recall — Class II2025-11-05
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- recall — Class II2025-11-05
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- recall — Class II2025-11-05
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- recall — Class II2025-07-02
Presence of foreign tablets/capsules.
- recall — Class II2025-02-12
Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
- recall — Class II2024-08-28
Superpotent Drug
- recall — Class II2024-07-24
Failed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.
- recall — Class II2024-06-26
Subpotent Drug
- recall — Class II2024-04-17
Superpotent Drug: The 3-month stability result for assay was found to be above specification limit
- recall — Class II2024-04-03
Failed Dissolution Specifications
- recall — Class III2024-02-21
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
- recall — Class III2024-02-21
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
- recall — Class II2024-02-07
Failed Dissolution Specifications
- recall — Class III2023-12-06
OOS for viscosity
- 4832023-09-29
Failure to comply with REMS Implementation System
- recall — Class II2023-07-19
Failed Moisture Limits: Water (moisture) content above the approved product specifications.
- recall — Class III2023-05-31
Labeling: Incorrect or Missing Package Insert
- recall — Class III2023-05-31
Labeling: Incorrect or Missing Package Insert
- recall — Class III2023-05-31
Labeling: Incorrect or Missing Package Insert
- recall — Class III2023-05-31
Labeling: Incorrect or Missing Package Insert
- recall — Class III2023-05-31
Labeling: Incorrect or Missing Package Insert
- recall — Class III2023-04-12
Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.
- recall — Class II2023-03-22
Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.
- recall — Class II2023-03-15
CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
- 4832022-11-10
Cleaning / Sanitizing / Maintenance
- 4832022-11-10
Equipment Design, Size and Location
- 4832022-11-10
Procedure Deviations Recorded and Justified
- recall — Class II2022-09-21
Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.
- recall — Class II2022-09-07
CGMP Deviations: A foreign matter identified as teflon was found in the Active Pharmaceutical Ingredient (API) used in the manufacture of Neomycin Sulfate Tablets, USP 500 mg.
- recall — Class III2022-08-17
Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.
- recall — Class II2022-08-10
Failed Dissolution Specifications: below specification limits for dissolution.
Is this Teva Pharmaceuticals USA, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.